收藏切换
Progress of sodium oligomannate in treatment of Alzheimer’s disease
收藏切换
PDF
Xiao-yun ZHAO1, Man-man ZHOU2, Mu-yu WU1, Xing-rong GUO3, Xin CHEN1
Chinese Journal of New Drugs and Clinical Remedies | 2025, 44(4) : 265 - 271
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2025, 44(4): 265-271
Review
Progress of sodium oligomannate in treatment of Alzheimer’s disease
Full
Xiao-yun ZHAO1, Man-man ZHOU2, Mu-yu WU1, Xing-rong GUO3, Xin CHEN1
Affiliations
  • 1. Department of Geriatrics, Dongfeng General Hospital of Sinopharm, Hubei University of Medicine, Shiyan HUBEI 442000,China
  • 2. Department of Neurology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou HE-NAN 450000, China
  • 3. Institute of Life Sciences, Hubei University of Medicine, Shiyan HUBEI 442000, China
Published: 2025-04-25 doi: 10.14109/j.cnki.xyylc.2025.04.05
Outline
收藏切换

Alzheimer’s disease (AD) is a slowly progressive degenerative disease of the central nervous system, and its incidence, prevalence and mortality are increasing year by year. At present, there is no cure for AD, mainly sympotomatic treatment with drugs, including cholinesterase inhibitors and megaline, but these drugs can only relieve clinical symptoms,but can not stop or reverse the development of AD. Aducanumab and lecanemab are targeted drugs developed for amyloid β-protein (Aβ) plaques in the brain in recent years, but they have not been fully popularized, and the safety and effectiveness of drugs need to be further verified. Sodium oligomannate is an innovative drug developed in China for the treatment of mild to moderate AD patients. It mainly improves cognitive function by regulating gut microbiota-brain axis. Other possible mechanisms include reducing brain Aβ deposition and tau protein phosphorylation, activating intestinal endocrine cell-vagus afferent pathway, inhibiting intracranial neuritidine, etc. With the clinical application of sodium oligomannate, more evidence shows that sodium oligomannate can not only improve the cognitive function of AD patients, but also have certain effects on the behavioral and psychiatric symptoms and daily living ability of patients. Combined treatment with other drugs may improve the clinical efficacy and reduce adverse reactions.

Alzheimer’s disease  /  cognitive dysfunction  /  sodium oligomannate
Xiao-yun ZHAO, Man-man ZHOU, Mu-yu WU, Xing-rong GUO, Xin CHEN. Progress of sodium oligomannate in treatment of Alzheimer’s disease[J]. Chinese Journal of New Drugs and Clinical Remedies, 2025 , 44 (4) : 265 -271 . DOI: 10.14109/j.cnki.xyylc.2025.04.05
Year 2025 volume 44 Issue 4
PDF
177
81
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2025.04.05
  • Receive Date:2024-09-30
  • Online Date:2025-12-15
  • Published:2025-04-25
Article Data
Affiliations
History
  • Received:2024-09-30
  • Accepted:2025-03-14
Funding
Affiliations
    1. Department of Geriatrics, Dongfeng General Hospital of Sinopharm, Hubei University of Medicine, Shiyan HUBEI 442000,China
    2. Department of Neurology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou HE-NAN 450000, China
    3. Institute of Life Sciences, Hubei University of Medicine, Shiyan HUBEI 442000, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2025.04.05
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT